WCWilliam G. Christen

William G. Christen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William G. Christen has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial

    by Yanbin Dong, Haidong Zhu, Li Chen, Ying Huang, William Christen, Nancy R. Cook, Trisha Copeland, Samia Mora, Julie E. Buring, I-Min Lee, et al.

    Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements. We recently reported that vitamin D supplementation with or without omega 3 fatty acids reduced autoimmune disease by 22% in the VITAL study. Objective: To investigate the effects of vitamin D3 and/or n-3 FAs on changes in systemic inflammatory biomarkers including pro- and anti-inflammatory cytokines over a 4-year period in the VITAL sub-cohort with in-person evaluations at the Center for Clinical Investigations (CCI) in Boston. Design: Serum levels of four inflammatory biomarkers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6, interleukin-10, and tumor necrosis factor-α) were measured in a total of 2713 samples from those 1054 VITAL/CCI participants (aged 64.9 ± 6.5 years, 49% female, 84% white, and 9% black) at baseline, year 2, and year 4 follow-up visits. Results: In multiple-adjusted models, vitamin D3 supplementation decreased serum hs-CRP levels by 19% at 2-year follow-up (nominal p = 0.007; p-value after multiple comparison adjustment = 0.028), but not at 4-year follow-up (nominal and adjusted p-values > 0.05). The effects of vitamin D3 on other inflammatory markers were not statistically significant either at year 2 or year 4 (all adjusted p-values > 0.05). Marine n-3 FAs were not significantly associated with changes of all the above inflammatory markers either at years 2 and 4, after multiple comparison adjustment (all p-values > 0.05). Conclusions: Vitamin D3 supplementation with or without n-3 FAs decreased hs-CRP by 19% at year 2, but not other inflammatory biomarkers at year 2 or year 4, while n-3 FAs with or without vitamin D3 did not significantly affect these biomarkers at either time point. Our findings support a potential role of vitamin D supplementation in modulating the chronic inflammatory process, systemic inflammation, and possibly autoimmune disease progression.


  • Open Access

    Efficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults

    by William G. Christen, Nancy R. Cook, JoAnn E. Manson, Julie E. Buring, I-Min Lee, Vadim Bubes, Georgina Friedenberg, Rimma Dushkes, Douglas Smith, Debra A. Schaumberg, et al.

    Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film causing a variety of symptoms and visual impairment.1,2 In the US, an estimated 16.4 million adults have been diagnosed with DED, and an additional 6 million adults have reported DED symptoms without a formal diagnosis.3 The pathophysiology of DED is incompletely understood, but typically involves a cycle of inflammation, including both innate and adaptive immune responses.4-6 Accordingly, management of DED often involves treatment with topical artificial tears plus limited-duration topical steroids; nonglucocorticoid immunomodulatory drugs, such as topical cyclosporine A; or the lymphocyte function–associated antigen (LFA)-1 antagonist lifitegrast.7


  • Dose-Response Models May Explain Age-Related Macular Degeneration and Vitamin Treatments—Reply

    by William G. Christen, Nancy R. Cook, JoAnn E. Manson

    In Reply We agree with Benke and Arslan that a higher dose of ω-3 fatty acids may be required before a beneficial effect on age-related macular degeneration (AMD) incidence or progression can be observed. In the Vitamin D and Omega-3 Trial (VITAL),3 the doses for the study participants were chosen after consideration of their anticipated effects on the primary study end points of the parent VITAL trial (cardiovascular disease and cancer) and of their anticipated balance of benefits and risks in a primary prevention setting. The dose (1 g/d) of ω-3 fatty acids tested (eicosapentaenoic acid and docosahexaenoic acid) was the one recommended by the American Heart Association for cardioprotection1 and has been shown to be beneficial in a secondary prevention population.2 While the optimal dose for AMD prevention is unknown, subgroup analyses in our study provided no evidence that the lack of effect of ω-3 fatty acids on AMD occurrence was modified by baseline plasma ω-3 level or reported intake of fish.3 Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.

  • Open Access

    Homocysteine Is Associated With Future Venous Thromboembolism in 2 Prospective Cohorts of Women

    by Aaron W. Aday, Edward K. Duran, Martin Van Denburgh, Eunjung Kim, William G. Christen, JoAnn E. Manson, Paul M Ridker, Aruna D. Pradhan

    Objective: Case-control studies have identified plasma homocysteine as a risk marker for venous thromboembolism (VTE). Prospective data, particularly among women, are sparse. We examined whether plasma homocysteine associates with incident VTE in 2 large prospective cohorts of women. Approach and Results: In the WHS (Women’s Health Study), a prospective cohort study of 27 555 women ≥45 years old and free of cardiovascular disease and VTE, we assessed baseline homocysteine concentration along with other thrombotic biomarkers for association with future VTE (n=743), pulmonary embolism (n=363), and deep vein thrombosis (n=545). We used a second cohort of 2672 women (n=102 VTE events) in the WAFACS (Women’s Antioxidant and Folic Acid Cardiovascular Study) to corroborate our findings. In age-adjusted analyses, elevated homocysteine, hsCRP (high-sensitivity C-reactive protein), fibrinogen, and sICAM-1 (soluble intercellular adhesion molecule-1) were associated with incident VTE ( P for extreme quartile comparisons and P -trend Q4 , 1.31 [95% CI, 1.06–1.63]). Elevated homocysteine levels were associated with unprovoked pulmonary embolism (HR Q4 , 2.13 [95% CI, 1.30–3.51]) and deep vein thrombosis (HR Q4 , 1.59 [95% CI, 1.05–2.40]) but not provoked events. In WAFACS, elevated homocysteine levels were also associated with VTE events ( P -trend 0.023). Conclusions: Higher plasma homocysteine levels associate with VTE events in 2 cohorts of middle-aged and older women. Among VTE subtypes, homocysteine was associated with unprovoked, but not provoked, events. These data suggest a plausible biological role for homocysteine in the development of VTE. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00000479, NCT00000541.


  • Open Access

    Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration

    by William G. Christen, Nancy R. Cook, JoAnn E. Manson, Julie E. Buring, Daniel I. Chasman, I-Min Lee, Vadim Bubes, Chunying Li, Margarette Haubourg, Debra A. Schaumberg, et al.

    Age-related macular degeneration (AMD) is a chronic, progressive disease of the central retina and the leading cause of severe, irreversible vision loss in US adults.1 Most cases of severe vision loss are due to the advanced form of the disease, either neovascular AMD or geographic atrophy.2 For persons with early AMD, there is usually little associated vision loss,2-4 but they are at elevated risk of progression to advanced AMD.5-8 Treatment is available in the form of anti–vascular endothelial growth factor therapy for patients with neovascular AMD,9-11 and supplements of antioxidants plus zinc for people with intermediate to advanced AMD.12,13 New therapeutic strategies are being explored in numerous ongoing trials, but most target the advanced forms of disease.14,15 Consequently, for the large majority of people with early or no AMD, there is no effective intervention other than lifestyle modifications, such as avoidance of cigarette smoking.16-18


  • Age‐related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B)

    by William G. Christen, Amy K. Darke, John M. Gaziano, Robert J. Glynn, Phyllis J. Goodman, Lori M. Minasian, Ian M. Thompson


  • Open Access

    Effect of Combined Treatment With Folic Acid, Vitamin B 6 , and Vitamin B 12 on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women

    by William G. Christen, Nancy R. Cook, Martin Van Denburgh, Elaine Zaharris, Christine M. Albert, JoAnn E. Manson

    Background: The aim of this study was to determine whether reducing plasma homocysteine concentrations with long‐term, combined treatment with folic acid, vitamin B 6 , and vitamin B 12 alters plasma biomarkers of inflammation and endothelial dysfunction in women at increased risk of cardiovascular disease. Methods and Results: We conducted a blood substudy of 300 treatment‐adherent participants (150 in the active treatment group, 150 in the placebo group) in the WAFACS (Women's Antioxidant and Folic Acid Cardiovascular Study), a randomized, double‐blind, placebo‐controlled trial testing a daily combination of folic acid (2.5 mg), vitamin B 6 (50 mg), vitamin B 12 (1 mg), or matching placebo, in cardiovascular disease prevention among women at increased risk of cardiovascular disease. Plasma concentration of 3 biomarkers of inflammation (C‐reactive protein, interleukin‐6, and fibrinogen) and a biomarker of endothelial dysfunction (intercellular adhesion molecule 1) were measured at baseline and at the end of treatment and follow‐up. After 7.3 years of combined treatment with folic acid, vitamin B 6 , and vitamin B 12 , homocysteine concentrations were reduced by 18% in the active treatment group as compared with the placebo group ( P P =0.77), interleukin‐6 ( P =0.91), intercellular adhesion molecule 1 ( P =0.38), or fibrinogen ( P =0.68). Conclusions: These findings indicate that long‐term, combined treatment with folic acid, vitamin B 6 , and vitamin B 12 lowers homocysteine concentrations, but does not alter major biomarkers of vascular inflammation, consistent with the lack of clinical cardiovascular disease benefit in the trial. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00000541.


  • Homocysteine, B Vitamins, MTHFR Genotype, and Incident Age-Related Macular Degeneration

    by William G. Christen, Daniel I. Chasman, Nancy R. Cook, Stephanie E. Chiuve, Paul M. Ridker, Julie E. Buring


  • Prospective study of plasma homocysteine, its dietary determinants, and risk of age-related macular degeneration in men

    by William G. Christen, Nancy R. Cook, Stephanie E. Chiuve, Paul M. Ridker, J. Michael Gaziano

    Purpose: Cross-sectional and case–control studies generally support a direct association between elevated plasma homocysteine and age-related macular degeneration (AMD), but data from prospective studies are limited. We examined the prospective relation of plasma homocysteine level, its dietary determinants, and risk of AMD in a large cohort of apparently healthy male physicians. Methods: During a mean follow-up of 11.2 years, we identified 146 incident cases of visually significant AMD (responsible for a reduction of visual acuity to 20/30 or worse), and 146 controls matched for age, smoking status, and time of blood draw. We measured concentration of homocysteine in blood samples collected at baseline using an enzymatic assay. and we assessed dietary intake of B vitamins and related compounds betaine and choline with a food frequency questionnaire administered at baseline. Results: AMD was not associated with plasma level of homocysteine; the multivariable-adjusted odds ratio (OR) of AMD comparing the highest and lowest quartile of homocysteine was 1.09 (95% confidence interval [95% CI]: 0.52–2.31; p for trend = 0.99). However, AMD was inversely associated with quartile of intake of total folate (OR: 0.55; 95% CI: 0.24–1.23; p for trend = 0.08), vitamin B6 from food (OR: 0.39; 95% CI: 0.17–0.88; p for trend = 0.01), and betaine (OR: 0.53; 95% CI: 0.22–1.27; p for trend = 0.048). Conclusions: These prospective data from a cohort of apparently healthy men do not support a major role for homocysteine in AMD occurrence, but do suggest a possible beneficial role for higher intake of several nutrients involved in homocysteine metabolism.


  • Open Access

    Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial

    by Phyllis J. Goodman, Catherine M. Tangen, Amy K. Darke, Kathryn B. Arnold, JoAnn Hartline, Monica Yee, Karen Anderson, Allison Caban-Holt, William G. Christen, Patricia A. Cassano, et al.

    The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a randomized, double-blind, placebo-controlled, prostate cancer prevention study funded by the National Cancer Institute and conducted by SWOG (Southwest Oncology Group). A total of 35,533 men were assigned randomly to one of four treatment groups (vitamin E + placebo, selenium + placebo, vitamin E + selenium, placebo + placebo). At the time of the trial’s development, NIH had invested substantial resources in evaluating the potential benefits of these antioxidants. To capitalize on the knowledge gained from following a large cohort of healthy, aging males on the effects of selenium and/or vitamin E, ancillary studies with other disease endpoints were solicited. Four ancillary studies were added. Each drew from the same population but had independent objectives and an endpoint other than prostate cancer. These studies fell into two categories: those prospectively enrolling and following participants (studies of Alzheimer’s disease and respiratory function) and those requiring a retrospective medical record review after a reported event (cataracts/age-related macular degeneration and colorectal screening). An examination of the challenges and opportunities of adding ancillary studies is provided. The impact of the ancillary studies on adherence to SELECT was evaluated using a Cox proportional hazards model. While the addition of ancillary studies appears to have improved participant adherence to the primary trial, this did not come without added complexity. Activation of the ancillary studies happened after the SELECT randomizations had begun resulting in accrual problems to some of the studies. Study site participation in the ancillary trials varied greatly and depended on the interest of the study site principal investigator. Procedures for each were integrated into the primary trial and all monitoring was done by the SELECT Data and Safety Monitoring Committee. The impact of the early closure of the primary trial was different for each of the ancillary trials. The ancillary studies allowed study sites to broaden the research opportunities for their participants. Their implementation was efficient because of the established infrastructure of the primary trial. Implementation of these ancillary trials took substantial planning and coordination but enriched the overall primary trial. NCT00006392-S0000 : Selenium and Vitamin E in Preventing Prostate Cancer (SELECT) (4 October 2000). NCT00780689-S0000A : Prevention of Alzheimer’s Disease by Vitamin E and Selenium (PREADVISE) (25 June 2002). NCT00784225-S0000B : Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000 (SEE) (31 October 2008). NCT00706121-S0000D : Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 (ACP) (26 June 2008). NCT00063453-S0000C : Vitamin E and/or Selenium in Preventing Loss of Lung Function in Older Men Enrolled on SELECT Clinical Trial SWOG-S0000 (26 June 2003).